Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-21
2006-11-21
Tsang, Cecilia J. (Department: 1654)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C568S367000, C568S368000, C568S369000, C568S370000, C568S371000, C568S372000, C556S137000
Reexamination Certificate
active
07138520
ABSTRACT:
In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.
REFERENCES:
patent: 4234500 (1980-11-01), Hoeschele et al.
patent: 4271085 (1981-06-01), Amundsen et al.
patent: 4284579 (1981-08-01), Meischen et al.
patent: 4291027 (1981-09-01), Hoeschel et al.
patent: 4416878 (1983-11-01), Klosa
patent: 4428943 (1984-01-01), Meischen et al.
patent: 4457926 (1984-07-01), Amundsen et al.
patent: 4462998 (1984-07-01), Amundsen et al.
patent: 4505928 (1985-03-01), Amundsen et al.
patent: 4560781 (1985-12-01), Totani et al.
patent: 4577018 (1986-03-01), Hlavka et al.
patent: 4590001 (1986-05-01), Stjernholm
patent: 4659849 (1987-04-01), Drobnik et al.
patent: 4732893 (1988-03-01), Pasini et al.
patent: 4760155 (1988-07-01), Heffernan et al.
patent: 4760156 (1988-07-01), Heffernan et al.
patent: 4793986 (1988-12-01), Serino et al.
patent: 4843161 (1989-06-01), Lippard et al.
patent: RE33071 (1989-09-01), Stjernholm
patent: 4870062 (1989-09-01), Kurono et al.
patent: 4873226 (1989-10-01), Talroy et al.
patent: 4912100 (1990-03-01), Ohno et al.
patent: 4921963 (1990-05-01), Skov et al.
patent: 4937262 (1990-06-01), Davidson
patent: 4952676 (1990-08-01), Heffernan et al.
patent: 4956454 (1990-09-01), Heffernan et al.
patent: 4980347 (1990-12-01), Ohno et al.
patent: 4992553 (1991-02-01), Von Angerer et al.
patent: 5026694 (1991-06-01), Skov et al.
patent: 5028726 (1991-07-01), Farrell
patent: 5104895 (1992-04-01), Spinelli et al.
patent: 5194644 (1993-03-01), Brunner et al.
patent: 5198564 (1993-03-01), Quianhuan
patent: 5225207 (1993-07-01), Barreau et al.
patent: 5238955 (1993-08-01), Brunner et al.
patent: 5256653 (1993-10-01), Keppler et al.
patent: 5380897 (1995-01-01), Hoeschele et al.
patent: 5409915 (1995-04-01), Farrell et al.
patent: 5484612 (1996-01-01), Brown
patent: 5498780 (1996-03-01), Yokoi et al.
patent: 5519155 (1996-05-01), Barnard et al.
patent: 5547982 (1996-08-01), Abrams et al.
patent: 5561042 (1996-10-01), Weis et al.
patent: 5624919 (1997-04-01), Farrell
patent: 5633243 (1997-05-01), Sugimura et al.
patent: 5714327 (1998-02-01), Houthoff et al.
patent: 5744497 (1998-04-01), Valsecchi et al.
patent: 5770591 (1998-06-01), Farrell
patent: 5902826 (1999-05-01), Mogi et al.
patent: 5985566 (1999-11-01), Houthoff et al.
patent: 6011166 (2000-01-01), Valsecchi et al.
patent: 6022892 (2000-02-01), Farrell et al.
patent: 6060616 (2000-05-01), Farrell et al.
patent: 6113934 (2000-09-01), Farrell et al.
patent: 6130245 (2000-10-01), Shaw
patent: 6133038 (2000-10-01), Houthoff et al.
patent: 6248531 (2001-06-01), Houthoff et al.
patent: 6313333 (2001-11-01), Da Re et al.
patent: 6333422 (2001-12-01), Sohn et al.
patent: 6340770 (2002-01-01), Kwon et al.
patent: 6384081 (2002-05-01), Berman
patent: 6469066 (2002-10-01), Dosch et al.
patent: 6605734 (2003-08-01), Roy et al.
patent: 6692734 (2004-02-01), Stewart et al.
patent: 6806289 (2004-10-01), Lippard et al.
patent: 6825330 (2004-11-01), Braman et al.
patent: 2004/0006051 (2004-01-01), Berube
patent: 1 262 778 (2002-04-01), None
patent: 0 169 645 (2006-01-01), None
patent: WO 96/35696 (1996-11-01), None
patent: WO 00/27847 (2000-05-01), None
patent: WO 03/017993 (2003-03-01), None
P. Berdagué, et al. J. Chem. Soc. Chem. Commun. (1994), pp. 1589-1590.
J. Altman, et al. Inorg. Chem. (1991) 30, pp. 4085-4088.
Arap, Wadih, et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,” Science, vol. 279, Jan. 16, 1998, pp. 377-380.
Brown, Steven J., et al., “1xrl, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin,” Science, vol. 261, Jul. 30, 1993, pp. 603-605.
Chen, Lie, et al., “Reduction of the anti-cancer drug analoguecis, trans, cis-[PtCl2(OCOCH3)2(NH3)2] by L-cysteine and L-methionine and its crystal structure,”J. Chem. Soc., Dalton Trans.,1999, pp. 1209-1212.
Cohen, Seth M., et al., “Cisplatin: From DNA Damage to Cancer Chemotherapy,” Progress in Nucleic Acid Research and Molecular Biology, vol. 67, 2001, pp. 93-130.
Dhara, S.C., A Rapid Method for the Synthesis ofcis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
Ellerby, H. Michael, et al., “Anti-cancer activity of targeted pro-apoptotic peptides,” Nature Medicine, vol. 5, No. 9, Sep. 1999, pp. 1032-1038.
Folkman, Judah, “What Is the Evidence That Tumors Are Angiogenesis Dependent?”, Journal of the National Cancer Institute, vol. 82, No. 1, Jan. 3, 1990, pp. 4-6.
Folkman, Judah, Alternative Strategies for Biologic Therapy, Chapter 30, Antiangiogenesis, pp. 743-753.
Folkman, Judah, et al., “Minireview, Angiogenesis,” The Journal of Biological Chemistry, vol. 267, No. 16, Issue of Jun. 5, 1992, pp. 1031-1034.
Giandomenico, Christen M., et al., Carboxylation of Kinetically Inert Platinum (IV) Hydroxy Complexes. An Entrée into Orally Active Platinum(IV) Antitumor Agents,Inorganic Chemistry,vol. 34, No. 5, 1995, pp. 1015-1021.
Hambley, T.W., et al., “Modifying the Properties of Platinum (IV) Complexes in Order to Increase Biological Effectiveness,” Journal of Inorganic Biochemistry, 77 (1999), pp. 3-12.
Hammes, Hans-Peter, et al., “Subcutaneous Injection of a Cyclic Peptide Antagonist of Vitronectin Receptor-Type Integrins Inhibits Retinal Neovascularization,” Nature Medicine, vol. 2, No. 5, May 1996, pp. 529-533.
Hart, Stephen L, et al., “Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide,” The Journal of Biological Chemistry, vol. 269, No. 17, Issue of Apr. 29, 1994, pp. 12468-12474.
Healy, Judith M., et al., “Peptide Ligands for Integrin αβ3Selected from Random Phage Display Libraries,”Biochemistry, vol. 34, No. 12, 1995, pp. 3948-3955.
Houston, Parul, et al., “Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging,” Federation of European Biochemical Societies, 2001, pp. 73-77.
Huang, Juch-Chin, et al., “HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease,”Proc. Natl. Acad. Sci. USA,vol. 91, Oct. 1994, pp. 10394-10398.
Jamieson, Elizabeth R., et al., “Structure, Recognition, and Processing of Cisplatin—DNA Adducts,” Chemical Reviews, 1999, pp. 2467-2498.
Kartalou, Maria, et al., “Recognition of cisplatin adducts by cellular proteins,” Mutation Research 478 (2001), pp. 1-21.
Koivunen, Erkki, et al., “Isolation of a Highly Specific Ligand for the α3β1Integrin from a Phage Display Library,” The Journal of Cell Biology, vol. 124, No. 5, Feb. 1994, pp. 373-380.
Koivunen, Erkki, et al., “Selection of Peptides Binding to the α3β1Integrin from Phage Display Library,” The Journal of Biological Chemistry, vol. 268, No. 27, Issue of Sep. 25, 1993, pp. 20205-20210.
Koivunen, Erkki, et al., “Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins,” Bio/Technology, vol. 13, Mar. 1995, pp. 265-270.
Lee, Keng-Boon, , et al., “Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro,” PNAS, vol. 99, No. 7, Apr. 2, 2002, pp. 4239-4244.
Lee, Young-A, et al., “Synthesis and Oral Antitumor Activity of Tetrakis (carboxylato) platinum (IV) Complexes,”J. Med. Chem.,vol. 43, No. 7, 2000, pp. 1409-1412.
Lemma, Kelemu, et al., “Kinetics and Mechanism for Reduction of the Anticancer Prodrug trans,trans,trans-[PtCl2(OH)2(c-C6H11NH2)(NH3)] (JM335) by Thiols,”Inorganic Chemistry,vol. 39, No. 8, 2000, pp. 1728-1734.
Lemma, Kelemu, et al., “Kinetics and Mechanism for reduction of anticancer-active tetrachloroam(m)ine platinu
Barnes Carmen M.
Barnes Katie R.
Haskel Ariel
Lippard Stephen J.
Kosar Andrew D.
Massachusetts Institute of Technology
Tsang Cecilia J.
LandOfFree
Coordination complexes having tethered therapeutic agents... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coordination complexes having tethered therapeutic agents..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coordination complexes having tethered therapeutic agents... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631326